Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Caramella, Marianna
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	350	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis	Active, not recruiting	2	21	Europe, US, RoW	GB2064	Galecto Biotech AB, OPIS s.r.l	Myelofibrosis	12/23	06/26
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)	Recruiting	N/A	319	Europe	Ropeginterferon alfa-2b, Besremi	FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS	Polycythemia Vera	09/26	12/26
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.	Recruiting	N/A	617	Europe, RoW		FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline	Myelofibrosis	12/25	12/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Caramella, Marianna
SENTRY, NCT04562389: Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Presentation of data from Phase 1 trial for 1L Myelofibrosis at ASH 2022 Dec 2022 - Dec 2022 : Data from trial in combination with ruxolitinib myelofibrosis Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Dec 2022 - Dec 2022: Data from trial in combination with ruxolitinib myelofibrosis at ASH 2022 Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Nov 2022 - Nov 2022: Data from P1 part of P1/2 XPORT-MF-034 trial for myelofibrosis at ASH 2022 Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Jun 2022 - Jun 2022: Preliminary data from P1 part of P1/2 XPORT-MF-034 trial in combination with ruxolitinib for myelofibrosis at ASCO 2022 Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 May 2022 - May 2022: Data from P1 study in combination with ruxolitinib in 1L myelofibrosis at ASCO 2022 More	Recruiting	3	350	Europe, Canada, US, RoW	Selinexor, KPT-330, Placebo, Ruxolitinib	Karyopharm Therapeutics Inc	Myelofibrosis	09/25	03/28
MYLOX-1, NCT04679870 / 2020-003087-45: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis	Active, not recruiting	2	21	Europe, US, RoW	GB2064	Galecto Biotech AB, OPIS s.r.l	Myelofibrosis	12/23	06/26
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)	Recruiting	N/A	319	Europe	Ropeginterferon alfa-2b, Besremi	FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS	Polycythemia Vera	09/26	12/26
ERNEST-3, NCT06533813: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.	Recruiting	N/A	617	Europe, RoW		FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline	Myelofibrosis	12/25	12/28